Ultragenyx Pharmaceutical (RARE) Cash from Operations (2013 - 2026)
Ultragenyx Pharmaceutical (RARE) reported Cash from Operations of 197000000.0 for Q1 2026, down 18.67% year-over-year from 242237037.04 in Q1 2025, and down 97.34% on a QoQ basis from 99829000.0 in Q4 2025.
Ultragenyx Pharmaceutical (RARE) has 14 years of Cash from Operations data on file, last reported at 197000000.0 in Q1 2026.
- Quarterly Cash from Operations fell 18.67% year-over-year to 197000000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 497000000.0 (down 27.67% YoY) and the FY2025 annual result came in at 466000000.0, down 12.56% from the prior year.
- Cash from Operations declined to 197000000.0 in Q1 2026 per RARE's latest filing, from 99829000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 66995000.0 in Q3 2024 and bottomed at 197000000.0 in Q1 2026.
- The 5-year median for Cash from Operations is 99829000.0 (2025), against an average of 113674411.76.
- The widest annual swing landed in 2022, when Cash from Operations slumped 66.24%; it then soared 43.16% in 2024.
- Tracing RARE's Cash from Operations over 5 years: stood at 90342000.0 in 2022, then increased by 6.91% to 84098000.0 in 2023, then grew by 5.69% to 79315000.0 in 2024, then dropped by 25.86% to 99829000.0 in 2025, then plunged by 97.34% to 197000000.0 in 2026.
- Per Business Quant, the three latest RARE Cash from Operations figures stand at 197000000.0 (Q1 2026), 99829000.0 (Q4 2025), and 91423000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.43 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.08 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.50 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn | -197.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -197.00 Mn |
| Mar 31, 2026 | -197.00 Mn |
| Dec 31, 2025 | -99.83 Mn |
| Dec 31, 2025 | -99.83 Mn |
| Sep 30, 2025 | -91.42 Mn |
| Sep 30, 2025 | -91.42 Mn |
| Jun 30, 2025 | -108.75 Mn |
| Jun 30, 2025 | -108.75 Mn |
| Mar 31, 2025 | -166.00 Mn |
| Mar 31, 2025 | -166.00 Mn |
| Dec 31, 2024 | -79.32 Mn |
| Dec 31, 2024 | -79.32 Mn |
| Sep 30, 2024 | -67.00 Mn |
| Sep 30, 2024 | -67.00 Mn |
| Jun 30, 2024 | -76.96 Mn |
| Jun 30, 2024 | -76.96 Mn |
| Mar 31, 2024 | -190.73 Mn |
| Mar 31, 2024 | -190.73 Mn |
| Dec 31, 2023 | -84.10 Mn |
| Dec 31, 2023 | -84.10 Mn |
| Sep 30, 2023 | -117.87 Mn |
| Sep 30, 2023 | -117.87 Mn |
| Jun 30, 2023 | -116.16 Mn |
| Jun 30, 2023 | -116.16 Mn |
| Mar 31, 2023 | -156.87 Mn |
| Mar 31, 2023 | -156.87 Mn |
| Dec 31, 2022 | -90.34 Mn |
| Dec 31, 2022 | -90.34 Mn |
| Sep 30, 2022 | -95.35 Mn |
| Sep 30, 2022 | -95.35 Mn |
| Jun 30, 2022 | -77.26 Mn |
| Jun 30, 2022 | -77.26 Mn |
| Mar 31, 2022 | -117.52 Mn |
| Mar 31, 2022 | -117.52 Mn |
| Dec 31, 2021 | -54.34 Mn |
| Dec 31, 2021 | -54.34 Mn |
| Sep 30, 2021 | -59.65 Mn |
| Sep 30, 2021 | -59.65 Mn |
| Jun 30, 2021 | -65.36 Mn |
| Jun 30, 2021 | -65.36 Mn |
| Mar 31, 2021 | -159.35 Mn |
| Mar 31, 2021 | -159.35 Mn |
| Dec 31, 2020 | -62.45 Mn |
| Dec 31, 2020 | -62.45 Mn |
| Sep 30, 2020 | -61.97 Mn |
| Sep 30, 2020 | -61.97 Mn |
| Jun 30, 2020 | 87.35 Mn |
| Jun 30, 2020 | 87.35 Mn |
| Mar 31, 2020 | -95.15 Mn |
| Mar 31, 2020 | -95.15 Mn |
| Dec 31, 2019 | -72.04 Mn |
| Dec 31, 2019 | -72.04 Mn |
| Sep 30, 2019 | -88.51 Mn |
| Sep 30, 2019 | -88.51 Mn |
| Jun 30, 2019 | -89.06 Mn |
| Jun 30, 2019 | -89.06 Mn |
| Mar 31, 2019 | -95.78 Mn |
| Mar 31, 2019 | -95.78 Mn |
| Dec 31, 2018 | -55.85 Mn |
| Dec 31, 2018 | -55.85 Mn |
| Sep 30, 2018 | -69.16 Mn |
| Sep 30, 2018 | -69.16 Mn |
| Jun 30, 2018 | -76.08 Mn |
| Jun 30, 2018 | -76.08 Mn |
| Mar 31, 2018 | -89.48 Mn |
| Mar 31, 2018 | -89.48 Mn |
| Dec 31, 2017 | -81.82 Mn |
| Dec 31, 2017 | -81.82 Mn |
| Sep 30, 2017 | -61.99 Mn |
| Sep 30, 2017 | -61.99 Mn |
| Jun 30, 2017 | -48.82 Mn |
| Jun 30, 2017 | -48.82 Mn |
| Mar 31, 2017 | -61.21 Mn |
| Mar 31, 2017 | -61.21 Mn |
| Dec 31, 2016 | -47.68 Mn |
| Dec 31, 2016 | -47.68 Mn |
| Sep 30, 2016 | -28.75 Mn |
| Sep 30, 2016 | -28.75 Mn |
| Jun 30, 2016 | -39.66 Mn |
| Jun 30, 2016 | -39.66 Mn |
| Mar 31, 2016 | -44.90 Mn |
| Mar 31, 2016 | -44.90 Mn |
| Dec 31, 2015 | -40.44 Mn |
| Dec 31, 2015 | -40.44 Mn |
| Sep 30, 2015 | -30.60 Mn |
| Sep 30, 2015 | -30.60 Mn |
| Jun 30, 2015 | -17.27 Mn |
| Jun 30, 2015 | -17.27 Mn |
| Mar 31, 2015 | -17.66 Mn |
| Mar 31, 2015 | -17.66 Mn |
| Dec 31, 2014 | -12.45 Mn |
| Dec 31, 2014 | -12.45 Mn |
| Sep 30, 2014 | -11.03 Mn |
| Sep 30, 2014 | -11.03 Mn |
| Jun 30, 2014 | -10.53 Mn |
| Jun 30, 2014 | -10.53 Mn |
| Mar 31, 2014 | -10.62 Mn |
| Mar 31, 2014 | -10.62 Mn |
| Dec 31, 2013 | -9.77 Mn |
| Dec 31, 2013 | -9.77 Mn |
| Sep 30, 2013 | -6.75 Mn |
| Sep 30, 2013 | -6.75 Mn |
| Jun 30, 2013 | -8.39 Mn |
| Jun 30, 2013 | -8.39 Mn |
| Mar 31, 2013 | -6.29 Mn |
| Mar 31, 2013 | -6.29 Mn |